NasdaqCM:EYES

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Second Sight Medical Products

Executive Summary

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Second Sight Medical Products's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EYES's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.0%

EYES

4.0%

US Medical Equipment

1.9%

US Market


1 Year Return

-84.4%

EYES

5.1%

US Medical Equipment

4.3%

US Market

Return vs Industry: EYES underperformed the US Medical Equipment industry which returned 5.1% over the past year.

Return vs Market: EYES underperformed the US Market which returned 4.3% over the past year.


Shareholder returns

EYESIndustryMarket
7 Day-1.0%4.0%1.9%
30 Day0%-0.6%2.7%
90 Day19.0%20.3%26.4%
1 Year-84.4%-84.4%6.1%5.1%6.5%4.3%
3 Year-90.2%-90.2%54.1%49.9%35.1%26.2%
5 Year-99.1%-99.1%106.3%90.1%67.0%48.4%

Price Volatility Vs. Market

How volatile is Second Sight Medical Products's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Second Sight Medical Products undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Second Sight Medical Products is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Second Sight Medical Products has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Second Sight Medical Products forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Second Sight Medical Products has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Second Sight Medical Products performed over the past 5 years?

-5.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EYES is currently unprofitable.

Growing Profit Margin: EYES is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EYES is unprofitable, and losses have increased over the past 5 years at a rate of -5.3% per year.

Accelerating Growth: Unable to compare EYES's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EYES is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.4%).


Return on Equity

High ROE: EYES's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Second Sight Medical Products's financial position?


Financial Position Analysis

Short Term Liabilities: EYES has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: EYES has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: EYES is debt free.

Reducing Debt: EYES's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EYES has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: EYES is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Second Sight Medical Products's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EYES's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EYES's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EYES's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EYES's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EYES's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Matt Pfeffer (62yo)

0.33

Tenure

US$84,000

Compensation

Mr. Matthew J. Pfeffer, also known as Matt, CPA, serves as an Acting Chief Executive Officer of Second Sight Medical Products, Inc. since March 27, 2020 and serves as its Director since May 2015. Mr. Pfeff ...


Leadership Team

NamePositionTenureCompensationOwnership
Matthew Pfeffer
Acting CEO & Director0.33yrUS$84.00k0.064% $14.8k
John Blake
CFO & Corporate Secretary2.33yrsUS$480.67k0.0076% $1.8k
Gunnar Bjorg
no datano datano data
Stephen Okland
Chief Strategy & Business Development Officer2.17yrsUS$615.76k0.013% $3.0k
Lisa Wilson
Founder & President of In-Site Communications and Investor Relations for Second Sightno datano datano data

2.2yrs

Average Tenure

55.5yo

Average Age

Experienced Management: EYES's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Matthew Pfeffer
Acting CEO & Director0.33yrUS$84.00k0.064% $14.8k
Aaron Mendelsohn
Independent Director22.5yrsUS$68.00k0.072% $16.7k
Gregg Williams
Independent Non-Executive Chairman2.33yrsUS$70.00k27.04% $6.3m
Jonathan McGuire
Director4.92yrsUS$939.70k0.089% $20.5k

5.0yrs

Average Tenure

61.5yo

Average Age

Experienced Board: EYES's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.9%.


Top Shareholders

Company Information

Second Sight Medical Products, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Second Sight Medical Products, Inc.
  • Ticker: EYES
  • Exchange: NasdaqCM
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$23.118m
  • Shares outstanding: 23.12m
  • Website: https://www.secondsight.com

Number of Employees


Location

  • Second Sight Medical Products, Inc.
  • 12744 San Fernando Road
  • Suite 400
  • Sylmar
  • California
  • 91342
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EYESNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2014
24PADB (Deutsche Boerse AG)YesCommon StockDEEURNov 2014

Biography

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/02 00:06
End of Day Share Price2020/07/01 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.